RE:RE:Good news soonThe stock price is clearly being controlled if you watch the ticker.
That being said, the 50 DMA has held on the weekly chart and the stock is back above the 200 DMA (daily chart).
The valuation is incorrect. Egrifta is worth $3-4. Trogarzo being valued at a total opportunity of $400 million? When it sells at over $100k per patient and the the TAM is 25k in the US? With European approval on the horizon in 2019?
Do we expect a report from RBC to hit after Labor Day?
Perhaps that will be the catalyst to get this back in to double digits and higher.
bfw